HDA appearance at EU Select Committee

The HDA’s Executive Director, Martin Sawer, appeared before the EU Exit Select Committee as part of the Committee’s assessment of the readiness of supply chains to cope in the event of a ‘no-deal’ Brexit.

Commenting on the risks associated with ‘no-deal,’ Martin Sawer said that the industry ‘would expect medicine shortages and a lot of price rises for the NHS pretty quickly, and some shortages in some constituencies for sure.’ He also warned that counterfeit and substandard drugs could find their way into pharmacies if the UK was forcibly detached from the Falsified Medicines Directive.

Watch the full discussion on the impact of a ‘no-deal’ Brexit on medicine and chemical industries here.